Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Adicet Bio (ACET) Stock Forecast & Price Target

Adicet Bio logo
$4.65 +0.12 (+2.58%)
As of 02:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Adicet Bio - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
7

Based on 9 Wall Street analysts who have issued ratings for Adicet Bio in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 1 has given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for ACET.

Consensus Price Target

$37.80
713.43% Upside
According to the 9 analysts' twelve-month price targets for Adicet Bio, the average price target is $37.80. The highest price target for ACET is $90.00, while the lowest price target for ACET is $18.00. The average price target represents a forecasted upside of 713.43% from the current price of $4.65.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ACET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Adicet Bio and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACET Analyst Ratings Over Time

TypeCurrent Forecast
10/20/25 to 10/20/26
1 Month Ago
9/20/25 to 9/20/26
3 Months Ago
7/22/25 to 7/22/26
1 Year Ago
10/20/24 to 10/20/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$37.80$46.80$48.80$90.67
Forecasted Upside713.43% Upside409.80% Upside469.43% Upside473.09% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ACET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Adicet Bio Stock vs. The Competition

TypeAdicet BioHealthcare CompaniesBroader Market
Consensus Rating Score
2.89
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside712.90% Upside1,390.75% Upside16.86% Upside
News Sentiment Rating
Neutral News

See Recent ACET News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/29/2026
Benchmark Co. logo
Benchmark
4 of 5 stars
 Reiterated RatingBuy
9/28/2026
Wedbush logo
Wedbush
5 of 5 stars
Robert Driscoll
Robert Driscoll
5 of 5 stars
Reiterated RatingOutperform$25.00 ➝ $28.00+329.32%
9/28/2026
HC Wainwright logo
HC Wainwright
4 of 5 stars
Robert Burns
5 of 5 stars
Boost TargetBuy$27.00 ➝ $34.00+366.26%
9/1/2026UpgradeStrong-Buy
8/21/2026 Reiterated RatingSell (D-)
8/6/2026Reiterated RatingBuy$100.00 ➝ $90.00+887.92%
3/25/2026 UpgradeStrong-Buy
1/6/2026Set TargetBuy$128.00 ➝ $18.00+120.86%
11/19/2025 Reiterated RatingMarket Perform
2/6/2025Reiterated RatingMarket Perform
The AI Infrastructure Rush Is ON — Watch VDTA (Ad)

Vertical Data Inc. (OTCQB: VDTA) is building the infrastructure layer behind the AI boom, from GPU hardware and financing to high-density data centers and edge computing. The company cites an AI infrastructure market that could exceed $800 billion by 2030, backed by a planned 20 MW Chicago data center targeting revenue in Q2 2027. A non-binding collaboration with Quantum eMotion adds a quantum-security angle, with GPU cluster integration pilots targeted for 2026.tc pixel

Find out why VDTA is a name to watch as AI infrastructure accelerates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:28 PM ET.


ACET Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Adicet Bio is $37.80, with a high forecast of $90.00 and a low forecast of $18.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There is currently 1 sell rating, 1 hold rating, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACET shares.

According to analysts, Adicet Bio's stock has a predicted upside of 713.43% based on their 12-month stock forecasts.

Over the previous 90 days, Adicet Bio's stock had 1 upgrade by analysts.

Adicet Bio has been rated by research analysts at Benchmark, Guggenheim, HC Wainwright, Jefferies Financial Group, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Adicet Bio more than other "healthcare" companies. The consensus rating for Adicet Bio is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ACET compares to other companies.


MarketBeat monitors more than a dozen sources for Adicet Bio analyst ratings, with the most recent rating issued on 9/29/2026.
From Our Partners